Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management

Current Treatment Options in Cardiovascular Medicine

Volumn 19, Issue 6, 2017, Pages

  Ballout, Fatima A ^a   Manshad, Ahmad S ^a   Okwuosa, Tochukwu M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardio oncology; Pulmonary hypertension; Pulmonary hypertension diagnosis

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; DASATINIB; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; PROTEASOME INHIBITOR;

BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DISEASE ASSOCIATION; HEART DISEASE; HUMAN; MALIGNANT NEOPLASM; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW;

EID: 85018991019     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-017-0543-5     Document Type: Review

References (100)

1. • Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50. Up-to-date findings and recommendations on the definition and diagnosis of PH presented in the Fifth World Symposium on PH
2. •• Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed). 2016;69(2):177. Consensus guidelines update for the classification of PH adopted from the Fifth World Symposium on Pulmonary Hypertension
3. • McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–97. A review article that provides an overview of the generally accepted management strategies for patients with PH in the context of recently published studies in the area
4. Rai PR, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:558–64.
5. Delom F, et al. Pulmonary arterial hypertension and cancer: an update on their similarities. Ann Res Rev Biol. 2014;4(1):20–37.
6. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219–63.
7. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465–72.
8. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011–20.
9. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17–21. Review
10. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50.
11. Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349(2):109–11.
12. Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):325–31.
13. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601–8.
14. Mandelstamm M. Über primäre Neubildungen des Herzens. Virchows Arch. 1923;245:43–54.
15. Blackmon SH, Rice DC, Correa AM, Mehran R, Putnam JB, Smythe WR, et al. Management of primary pulmonary artery sarcomas. Ann Thorac Surg. 2009;87:977–84.
16. Mussot S, Ghigna MR, Mercier O, Fabre D, Fadel E, Le Cesne A, et al. Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma. Eur J Cardiothorac Surg. 2013;43:787–93.
17. Wong HH, Gounaris I, McCormack A, et al. Presentation and management of pulmonary artery sarcoma. Clinical Sarcoma Research. 2015;5:3.
18. Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 2008;4.
19. Dasanu CA, Codreanu I, Mesologites T, Ali S, Sullivan P, Jethava A. Western variant of brain intravascular lymphoma displaying three distinct evolutive radiologic stages. Conn Med. 2014;78(2):73–6.
20. Walls JG, Hong YG, Cox JE, et al. Pulmonary intravascular lymphomatosis: presentation with dyspnea and air trapping. Chest. 1999;115:1207–10.
21. Sinha N, Lantigua L, Niazi M, et al. An elderly lady with fever of unknown etiology and severe pulmonary hypertension: intravascular lymphoma-an elusive diagnosis. Case Rep Med. 2013;2013:153798.
22. Snyder LS, Harmon KR, Estensen RD. Intravascular lymphomatosis (malignant angioendotheliomatosis) presenting as pulmonary hypertension. Chest. 1989;96(5):1199–200.
23. Aouba A, Diop S, Saadoun D, et al. Severe pulmonary arterial hypertension as initial manifestation of intravascular lymphoma: case report. Am J Hematol. 2005;79:46–9.
24. Kotake T, Kosugi S, Takimoto T, Nakata S, Shiga J, Nagate Y, Nakagawa T, Take H, Katagiri S. Intravascular large B-cell lymphoma presenting pulmonary arterial hypertension as an initial manifestation. Intern Med. 2010;49(1):51–4.
25. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006;27:1056–65.
26. McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008;133:507–16.
27. Harari S, Torre O, Moss J. Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev. 2011;20:34–44.
28. Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151:527–33.
29. Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Groupe d’Etudes et de Recherche sur les maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore). 1999;78:321–37.
30. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest. 1999;115:1041–52.
31. Ryu JH, Moss J, Beck GJ, et al. The NHLBI Lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173:105–11.
32. Cottin V, Archer F, Leroux C, et al. Milestones in lymphangioleiomyomatosis research. Eur Respir Rev. 2011;20:3–6.
33. Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J. 2012;40:630–40.
34. Taveira-DaSilva AM, Hathaway OM, Sachdev V, et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest. 2007;132:1573–8.
35. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002;277:30958–67.
36. Krymskaya VP, Snow J, Cesarone G, et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J. 2011;25:1922–33.
37. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104(4):593–604.
38. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5(6):477–85.
39. Cawthon RM, Weiss R, Xu G, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 1990;62:193–201.
40. Cawthon RM, O'Connell P, Buchberg AM, et al. Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts. Genomics. 1990;7:555–65.
41. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990;62:187–92.
42. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181–6.
43. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994;330:597–601.
44. Wild A, Kalff-Suske W, Vortkamp A, et al. Point mutations in human GLI3 cause Greig syndrome. Hum Mol Genet. 1997;6:1979–84.
45. Norton KK, Xu J, Gutmann DH. Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis. 1995;2(1):13–21.
46. Hamilton SJ, Friedman JM. Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Genet. 2000;58(5):341–4.
47. Montani D, Coulet F, Girerd B, Eyries M, Bergot E, Mal H, Biondi G, Dromer C, Hugues T, Marquette C, O'Connell C, O'Callaghan DS, Savale L, Jaïs X, Dorfmüller P, Begueret H, Bertoletti L, Sitbon O, Bellanné-Chantelot C, Zalcman G, Simonneau G, Humbert M, Soubrier F. Pulmonary hypertension in patients with neurofibromatosis type I. Medicine (Baltimore). 2011;90(3):201–11.
48. Samuels N, Berkman N, Milgalter E, Bar-Ziv J, Amir G, Kramer MR. Pulmonary hypertension secondary to neurofibromatosis: intimal fibrosis versus thromboembolism. Thorax. 1999;54:858–9.
49. Stewart DR, Cogan JD, Kramer MR, Miller Jr WT, Christiansen LE, Pauciulo MW, Messiaen LM, Tu GS, Thompson WH, Pyeritz RE, Ryu JH, Nichols WC, Kodama M, Meyrick BO, Ross DJ. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? Chest. 2007;132:798–808.
50. Miyano S, Izumi S, Takeda Y, Tokuhara M, Mochizuki M, Matsubara O, et al. Pulmonary tumor thrombotic microangiopathy. J Clin Oncol. 2007;25:597–9.
51. Godbole R, Ghatol A, Betancourt J, Sacoolidge J, Kamangar N. Pulmonary tumor thrombotic Microangiopathy: clinical, radiologic, and histologic correlation. Journal of Clinical Imaging Science. 2015;5:44.
52. von Herbay A, Illes A, Waldherr R, Otto HF. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 1990;66:587–92.
53. Uruga H, Fujii T, Kurosaki A, Hanada S, Takaya H, Miyamoto A, et al. Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med. 2013;52:1317–23.
54. Kayatani H, Matsuo K, Ueda Y, Matsushita M, Fujiwara K, Yonei T, et al. Pulmonary tumor thrombotic microangiopathy diagnosed antemortem and treated with combination chemotherapy. Intern Med. 2012;51:2767–70.
55. Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G. Baccarani M; GIMEMA acute leukemia working party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–8.
56. Pullamsetti SS, Berghausen EM, Dabral S, et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2012;32:1354–65. Leukemia. Blood. 2011;118:6521–6528
57. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128–37.
58. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90(11):1060–4.
59. Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4:99–105.
60. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967–8.
61. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108(7):2165–72.
62. Siegel D, Martin T, Nooka A, et al. Integrated saferty profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–61.
63. Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, Dumas SJ, Raymond N, Lau E, Savale L, Jaïs X, Sitbon O, Simonneau G, Stenmark K, Cohen-Kaminsky S, Humbert M, Montani D, Perros F. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356–71.
64. Nicod P, Moser KM. Primary pulmonary hypertension: the risk and benefit of lung biopsy. Circulation. 1989;80:1486–8.
65. Montani D, Achouh L, Dorfmüller P, Le Pavec J, Sztrymf B, Tchérakian C, Rabiller A, Haque R, Sitbon O, Jaïs X, Dartevelle P, Maître S, Capron F, Musset D, Simonneau G, Humbert M. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008;87:220–33.
66. Perros F, Cohen-Kaminsky S, Gambaryan N, Girerd B, Raymond N, Klingelschmitt I, Huertas A, Mercier O, Fadel E, Simonneau G, Humbert M, Dorfmüller P, Montani D. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2013;187:189e196.
67. Hoorn CM, Wagner JG, Petry TW, Roth RA. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol. 1995;130:87e94.
68. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamidemediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004;64:1570e1574. 38
69. Ohtani T, Nakamura T, Toda K-I, Furukawa F. Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell. FEBS Lett. 2006;580:1597e1600.
70. Cooper Jr JA, Merrill WW, Reynolds HY. Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism: possible mechanisms of pulmonary pharmacotoxicity. Am Rev Respir Dis. 1986;134:108e114. 37
71. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology. 1996;24:830e837. 40
72. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104:1574e1577.
73. •• Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P, Fadel E, Sitbon O, Simonneau G, Tregouët D-A, Humbert M, Soubrier F. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46:65e69. By using whole-exome sequencing, this study detected recessive mutations in EIF2AK4 (also called GCN2) that cosegregated with PVOD in 13 families studied. These findings point to EIF2AK4 as the major gene that is linked to PVOD development
74. Kramer MR, Estenne M, Berkman N, Antoine M, de Francquen P, Lipski A, Jacobovitz D, Lafair J. Radiation-induced pulmonary venoocclusive disease. Chest. 1993;104:1282e1284.
75. Ghobadi G, Bartelds B, van der Veen SJ, Dickinson MG, Brandenburg S, Berger RM, Langendijk JA, Coppes RP, van Luijk P. Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension. Thorax. 2012;67:334–41.
76. Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF. Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant. 1996;18:755–60.
77. Kuga T, Kohda K, Hirayama Y, Matsumoto S, Nakazawa O, Ando M, Ezoe A, Nobuoka A, Mochizuki C. Pulmonary veno-occlusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Int J Hematol. 1996;64:143–50.
78. Troussard X, Bernaudin JF, Cordonnier C, Fleury J, Payen D, Briere J, Vernant JP. Pulmonary veno-occlusive disease after bone marrow transplantation. Thorax. 1984;39:956–7.
79. Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant. 2008;41:677–86.
80. Gottlieb, Roberta, and Puja Mehta (2016). Pulmonary Hypertension and Cancer. In: Cardio-oncology Principles, Prevention and Management (pp273–282). Elsevier Science.
81. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.
82. Vachiery JL, Adir Y, Barbera JA, Champion HC, Coghlan JG, Cottin V, DeMarco T, Galiè N, Ghio S, Gibbs JS, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Seeger W. Pulmonary hypertension due to left heart disease. J Am Coll Cardiol. 2013;62:D100–8.
83. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, Gomberg-Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza RL. World Health Organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the pulmonary hypertension Council of the International Society for heart and lung transplantation. J Heart Lung Transplant. 2012;31:913–33.
84. • Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013;62:D92–9. Up-to-date findings and recommendations on new diagnostic and treatment algorithms for Chronic Thromboembolic Pulmonary Hypertension presented in the Fifth Wolrd Symposium on PH
85. Stamm JA, Risbano MG, Mathier MA. Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ. 2011;1(2):138–59.
86. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association. J Am Coll Cardiol. 2009;53:1573–619.
87. Galiè N, Ghofrani AH. New horizons in pulmonary arterial hypertension therapies. Eur Respir Rev. 2013;22(130):503–14.
88. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twentythree cases. Arthritis Rheum. 2008;58:521–31.
89. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med. 2002;346:683–93.
90. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811–21.
91. • Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, Le Coutre PD, Saglio G. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phrase treated with imitinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27:1310–5. A retrospective cohort analysis from three randomized phase III studies revealed lower incidence of cardiovascular events in patients treated with imatinib compared with patients not treated with TKI or patients treated with nilotinib. This study suggested that imatinib may be inherently protective against vascular events
92. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412–3.
93. • Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127:1128–38. A 24-week randomized, double-blind, placebo-controlled trial showed that imatinib therapy could improve cardiac output with a modest reduction in mPAP in patients with severe pulmonary arterial hypertension despite therapy with at least two standard PAH drugs
94. Frost AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, Galié N, Hassoun PM, Klose H, Matsubara H, Morrell NW, Peacock AJ, Pfeifer M, Simonneau G, Tapson VF, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser JM, Quinn DA, Ghofrani HA. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. 2015;34(11):1366–75.
95. Wang X, Ibrahim YF, Das D, Zungu-Edmondson M, Shults NV, Suzuki YJ. Carfilzomib reverses pulmonary arterial hypertension. Cardiovasc Res. 2016;110(2):188–99.
96. Suzuki YJ, Ibrahim YF, Shults NV. Apoptosis-based therapy to treat pulmonary arterial hypertension. Journal of rare diseases research & treatment. 2016;1(2):17–24.
97. Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, Fedullo PF, Jamieson SW. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg. 2012;94:97–103.
98. Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, Wheaton E, Klein A, Arrowsmith J, Hall R, Jenkins D. Circulatory arrest versus cerebral perfu- sion during pulmonary endarterectomy surgery (PEACOG): a randomised con- trolled trial. Lancet. 2011;378:1379–87.
99. Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, Ilkjaer LB, Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Dartevelle P. Sur- gical management and outcome of patients with chronic thromboembolic pul- monary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141:702–10.
100. Jenkins D, Mayer E, Screaton N, Madani M. State-of-the-art chronic thrombo- embolic pulmonary hypertension diagnosis and management. Eur Respir Rev. 2012;21:32–9.